Eramet SA

As of June 30, 2026, Eramet-SLN carries a market capitalization of 1.57B, placing it among publicly traded companies globally. Its enterprise value stands at 4.85B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Eramet-SLN's next confirmed earnings release is scheduled for February 24, 2027.

As of June 30, 2026, Eramet-SLN has 28.66M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Eramet-SLN maintains a current ratio of 2.04, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 13, 2026, Eramet-SLN's stock has declined approximately 27.60% over the past 52 weeks. The 50-day moving average sits at 70.65, while the 200-day moving average is 85.42.

As of June 30, 2026, Eramet-SLN holds 1.43B in cash and equivalents against 3.56B in total debt, resulting in a net debt position of 2.09B. Total book value stands at 503.83M, with working capital of 1.56B providing operational flexibility.